Dianthus Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, clasepruba...
Latest News
17 hours ago · seekingalpha.com
Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 TranscriptDianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
8 days ago · zacks.com
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?The mean of analysts' price targets for Dianthus Therapeutics, Inc. (DNTH) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
12 days ago · zacks.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue EstimatesDianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.
14 days ago · globenewswire.com
Dianthus Therapeutics to Participate in Five Investor Conferences During NovemberNEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in five investor conferences.
1 month ago · globenewswire.com
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaNEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced it was selected by Great Place To Work® and Fortune magazine for the 2026 Fortune Best Workplaces in BioPharma™ List. This is Dianthus' inaugural appearance on the list, ranking among the top 30 small- and medium-sized biotechnology and pharmaceutical companies in the United States. The Company was recognized for fostering a high-trust and engaging workplace culture.
2 months ago · globenewswire.com
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingNEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Florida.
2 months ago · seekingalpha.com
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptDianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
3 months ago · globenewswire.com
Dianthus Therapeutics to Participate in Three Investor Conferences During SeptemberNEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in three investor conferences.
3 months ago · seekingalpha.com
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull CaseDianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after Sanofi's setback.
3 months ago · zacks.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue EstimatesDianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove DNTH